Scarica l'app Stockscreener
14.77
0.47%
-0.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Precedente Chiudi:
$14.84
Aprire:
$15.24
Volume 24 ore:
6.50M
Relative Volume:
1.57
Capitalizzazione di mercato:
$11.46B
Reddito:
$220.00K
Utile/perdita netta:
$-1.08B
Rapporto P/E:
-10.22
EPS:
-1.4448
Flusso di cassa netto:
$-326.53M
1 W Prestazione:
-15.79%
1M Prestazione:
-15.79%
6M Prestazione:
-19.33%
1 anno Prestazione:
-25.14%
Intervallo 1D:
$14.65
$15.35
Intervallo di 1 settimana:
$14.17
$16.84
Portata 52W:
$13.83
$30.98
Summit Therapeutics Inc Stock (SMMT) Company Profile
Nome
Summit Therapeutics Inc
Settore
Industria
Telefono
305-203-2034
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
14.77 | 11.52B | 220.00K | -1.08B | -326.53M | -1.4448 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-08 | Iniziato | Stifel | Buy |
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-17 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-17 | Iniziato | Barclays | Underweight |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Neutral |
| 2025-07-01 | Iniziato | UBS | Buy |
| 2025-06-11 | Iniziato | Leerink Partners | Underperform |
| 2025-03-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | Goldman | Buy |
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-06 | Iniziato | Jefferies | Buy |
| 2024-11-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-27 | Downgrade | Citigroup | Buy → Neutral |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-07 | Iniziato | Citigroup | Buy |
| 2024-03-26 | Iniziato | Stifel | Buy |
| 2018-06-28 | Downgrade | Janney | Buy → Neutral |
| 2018-05-02 | Iniziato | Janney | Buy |
| 2018-04-12 | Reiterato | Needham | Buy |
| 2018-02-13 | Iniziato | BTIG Research | Buy |
| 2018-01-04 | Iniziato | SunTrust | Buy |
| 2017-12-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-05 | Reiterato | Needham | Buy |
| 2016-09-16 | Iniziato | H.C. Wainwright | Buy |
| 2015-03-30 | Iniziato | Needham | Buy |
| 2015-03-30 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
Summit Therapeutics (SMMT) Reveals Phase II AK112-206 Trial Data - Insider Monkey
Summit falls despite Phase 3 ivonescimab data in NSCLC - MSN
Insider Buying: Manmeet Soni Acquires 50,000 Shares of Summit Th - GuruFocus
Summit Therapeutics COO & CFO Soni buys $722,250 in stock By Investing.com - Investing.com South Africa
Summit Therapeutics co-CEO Zanganeh Mahkam buys $1.46m stock By Investing.com - Investing.com South Africa
Summit Therapeutics co-CEO Zanganeh Mahkam buys $1.46m stock - Investing.com UK
Summit Therapeutics (SMMT) Co‑CEO associated trust purchases 100,000 shares at $14.60 - Stock Titan
Summit Therapeutics (SMMT) co-CEO buys 100K shares via revocable trust - Stock Titan
Summit Therapeutics Insider Bought Shares Worth $722,250, According to a Recent SEC Filing - marketscreener.com
Summit Therapeutics COO, CFO Purchased Shares Worth Over $722K - TradingView
Summit Therapeutics COO & CFO Soni buys $722,250 in stock - Investing.com
Executive Manmeet Singh Soni buys 50K Summit Therapeutics (SMMT) shares - Stock Titan
Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference - Yahoo Finance
All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy - Yahoo Finance
Summit (SMMT) Reports Positive Phase III Overall Survival Data for Ivonescimab in Advanced NSCLC - Insider Monkey
SMMT News | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Assessing Summit Therapeutics (SMMT) Valuation After A Mixed Share Price And Long Term Return Profile - Yahoo Finance
Summit Therapeutics Inc. (SMMT) Discusses Plenary Session Updates and Recent Clinical Data Following Major Oncology CongressSlideshow (NASDAQ:SMMT) 2026-06-03 - Seeking Alpha
Summit Therapeutics Enables Affiliate and Insider Share Purchases - TipRanks
Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock By Investing.com - Investing.com Canada
Summit Therapeutics directors, executives likely to buy shares under ATM program - TradingView
Summit Therapeutics (SMMT) leaders may buy shares via existing ATM - Stock Titan
Why Is SMMT Stock Surging Over 10% In Overnight Trading? - Stocktwits
Wells Fargo Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Biotech Movers: Moderna, Iovance, ALHC, SMMT in Focus - Gotrade
Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (SMMT), Oculis Holding (OCS) and Cogent Biosciences (COGT) - The Globe and Mail
Cantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical Developments - Insider Monkey
Summit Therapeutics (SMMT) Sheds 10.4%, This Analyst is Pessimistic - Insider Monkey
Summit Therapeutics (SMMT) Shares Drop Despite Positive Cancer T - GuruFocus
Exclusive BAC Article: Akeso And Summit: Positive China HARMONi-6 Trial Ivonescimab Squamous NSCLC, HARMONi-3 Data From Summit 2nd Half 2026 & 1st Half 2027, And Catalysts (OTCMKTS:AKESF) - Seeking Alpha
Summit Therapeutics (SMMT) Slides As Bearish Calls Mount - StocksToTrade
Summit Therapeutics Inc. (SMMT) once dropped over 12.8%, approaching the May 1st low of $15.14. - Bitget
Summit Therapeutics Reports Promising Phase II Ivonescimab Results in Metastatic Colorectal Cancer at ASCO 2026 - Minichart
Summit Therapeutics slides as traders digest ASCO ivonescimab update - Quiver Quantitative
Summit Therapeutics (SMMT) Revenue BreakdownMain Composition - Moomoo
What's Going On With Summit Therapeutics Stock On Monday? - Benzinga
A Quick Look at Today's Ratings for Summit Therapeutics(SMMT.US), With a Forecast Between $7.7 to $40 - Moomoo
Wall Street Analysts Think Summit Therapeutics (SMMT) Could Surge 67.1%: Read This Before Placing a Bet - Yahoo Finance
Bernstein reiterates Summit Therapeutics stock Underperform on trial concerns By Investing.com - Investing.com Canada
Summit Therapeutics stock maintained at Overweight by Cantor on positive trial data - Investing.com Canada
Stifel reiterates Summit Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Summit drops as concerns over older patients cloud cancer trial data - marketscreener.com
Summit Therapeutics Reports Strong Interim Ivonescimab Phase II Data - TipRanks
Summit Therapeutics (SMMT) posts positive ASCO 2026 ivonescimab survival and response data - Stock Titan
Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's - marketscreener.com
Summit Therapeutics Inc. (SMMT) Stock Analysis: A Potential 62.66% Upside In Biotech Innovation - DirectorsTalk Interviews
SMMT Stock Surges Overnight: Cancer Drug Survival Win Raises The Bar As PFE, BMY, MRK Chase Keytruda's Successor - Yahoo Finance
Summit Therapeutics (SMMT) Unveils Promising Results from Colore - GuruFocus
Summit Therapeutics (SMMT) to Present Phase III Trial Results at ASCO 2026 - GuruFocus
13 Best Short Squeeze Stocks to Invest In - Insider Monkey
Summit Therapeutics Inc. (SMMT) Stock Price, News, Quote & History - Yahoo Finance
Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Summit Therapeutics Inc Azioni (SMMT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Zanganeh Mahkam | Co-Chief Executive Officer |
Jun 04 '26 |
Buy |
14.60 |
100,000 |
1,460,000 |
25,824,474 |
| Soni Manmeet Singh | COO and CFO |
Jun 04 '26 |
Buy |
14.45 |
50,000 |
722,250 |
3,123,603 |
| Xia Yu | Director |
Oct 21 '25 |
Buy |
18.74 |
533,617 |
9,999,983 |
32,057,147 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
1.13%
3.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):